Annexins are instrumental for efficient plasma membrane repair in cancer cells

Seminars in Cell and Developmental Biology

Volumn 45, Issue , 2015, Pages 32-38

  Lauritzen, Stine Prehn ^a   Boye, Theresa Louise ^a   Nylandsted, Jesper ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Actin cytoskeleton; Annexin A2; Annexins; Breast cancer; Cancer; Metastasis; Plasma membrane repair; S100 proteins; S100A11

Indexed keywords

ANNEXIN; PROTEIN S 100;

ACTIN FILAMENT; CANCER CELL; CELL INVASION; CELL MEMBRANE; CELL REGENERATION; DRUG TARGETING; HEALING; HUMAN; METASTASIS; NONHUMAN; PLASMA MEMBRANE REPAIR; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; TUMOR INVASION; ANIMAL; BREAST TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; WOUND HEALING;

ACTIN CYTOSKELETON; ANIMALS; ANNEXINS; BREAST NEOPLASMS; CELL MEMBRANE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; S100 PROTEINS; WOUND HEALING;

EID: 84949198217     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.10.028     Document Type: Review

References (85)

1. McNeil P.L., Khakee R. Disruptions of muscle fiber plasma membranes. Role in exercise-induced damage. Am. J. Pathol. 1992, 140:1097-1109.
2. Gajic O., Lee J., Doerr C.H., Berrios J.C., Myers J.L., Hubmayr R.D. Ventilator-induced cell wounding and repair in the intact lung. Am. J. Respir. Crit. Care Med. 2003, 167:1057-1063.
3. Bansal D., Miyake K., Vogel S.S., Groh S., Chen C.C., Williamson R., McNeil P.L., Campbell K.P. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172.
4. Defour A., Van der Meulen J.H., Bhat R., Bigot A., Bashir R., Nagaraju K., Jaiswal J.K. Dysferlin regulates cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion. Cell Death Dis. 2014, 5:e1306.
5. Jaiswal J.K., Marlow G., Summerill G., Mahjneh I., Mueller S., Hill M., Miyake K., Haase H., Anderson L.V., Richard I., Kiuru-Enari S., McNeil P.L., Simon S.M., Bashir R. Patients with a non-dysferlin Miyoshi myopathy have a novel membrane repair defect. Traffic 2007, 8:77-88.
6. Cheng X., Zhang X., Gao Q., Ali Samie M., Azar M., Tsang W.L., Dong L., Sahoo N., Li X., Zhuo Y., Garrity A.G., Wang X., Ferrer M., Dowling J., Xu L., Han R., Xu H. The intracellular Ca(2+) channel MCOLN1 is required for sarcolemma repair to prevent muscular dystrophy. Nature Med. 2014, 20:1187-1192.
7. Yasuda S., Townsend D., Michele D.E., Favre E.G., Day S.M., Metzger J.M. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005, 436:1025-1029.
8. Weisleder N., Takizawa N., Lin P., Wang X., Cao C., Zhang Y., Tan T., Ferrante C., Zhu H., Chen P.J., Yan R., Sterling M., Zhao X., Hwang M., Takeshima M., Cai C., Cheng H., Takeshima H., Xiao R.P., Ma J. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci. Transl. Med. 2012, 4:139ra85.
9. Jia Y., Chen K., Lin P., Lieber G., Nishi M., Yan R., Wang Z., Yao Y., Li Y., Whitson B.A., Duann P., Li H., Zhou X., Zhu H., Takeshima H., Hunter J.C., McLeod R.L., Weisleder N., Zeng C., Ma J. Treatment of acute lung injury by targeting MG53-mediated cell membrane repair. Nature Commun. 2014, 5:4387.
10. Huynh C., Roth D., Ward D.M., Kaplan J., Andrews N.W. Defective lysosomal exocytosis and plasma membrane repair in Chediak-Higashi/beige cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16795-16800.
11. Tam C., Idone V., Devlin C., Fernandes M.C., Flannery A., He X., Schuchman E., Tabas I., Andrews N.W. Exocytosis of acid sphingomyelinase by wounded cells promotes endocytosis and plasma membrane repair. J. Cell Biol. 2010, 189:1027-1038.
12. Howard A.C., McNeil A.K., Xiong F., Xiong W.C., McNeil P.L. A novel cellular defect in diabetes: membrane repair failure. Diabetes 2011, 60:3034-3043.
13. Jaiswal J.K., Lauritzen S.P., Scheffer L., Sakaguchi M., Bunkenborg J., Simon S.M., Kallunki T., Jaattela M., Nylandsted J. S100A11 is required for efficient plasma membrane repair and survival of invasive cancer cells. Nat. Commun. 2014, 5:3795.
14. Jaiswal J.K., Nylandsted J. S100 and annexin proteins identify cell membrane damage as the Achilles heel of metastatic cancer cells. Cell Cycle 2015, 14:502-509.
15. Nylandsted J. Plasma membrane repair provides a new strategy for targeting metastatic cancer cells. Can. Cell Microenviron. 2015, 2:e446. 10.14800/ccm.446.
16. Hoffman J.F. On red blood cells, hemolysis and resealed ghosts. Adv. Exp. Med. Biol. 1992, 326:1-15.
17. Abreu-Blanco M.T., Verboon J.M., Parkhurst S.M. Single cell wound repair: dealing with life's little traumas. Bioarchitecture 2011, 1:114-121.
18. Jaiswal J.K. Calcium - how and why?. J. Biosci. 2001, 26:357-363.
19. McNeil P.L., Vogel S.S., Miyake K., Terasaki M. Patching plasma membrane disruptions with cytoplasmic membrane. J. Cell Sci. 2000, 113(Pt 11):1891-1902.
20. Steinhardt R.A., Bi G., Alderton J.M. Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release. Science 1994, 263:390-393.
21. Terasaki M., Miyake K., McNeil P.L. Large plasma membrane disruptions are rapidly resealed by Ca2+-dependent vesicle-vesicle fusion events. J. Cell Biol. 1997, 139:63-74.
22. Reddy A., Caler E.V., Andrews N.W. Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell 2001, 106:157-169.
23. McNeil P.L. Repairing a torn cell surface: make way, lysosomes to the rescue. J. Cell Sci. 2002, 115:873-879.
24. Lorusso A., Covino C., Priori G., Bachi A., Meldolesi J., Chieregatti E. Annexin2 coating the surface of enlargeosomes is needed for their regulated exocytosis. EMBO J. 2006, 25:5443-5456.
25. Sharma N., Medikayala S., Defour A., Rayavarapu S., Brown K.J., Hathout Y., Jaiswal J.K. Use of quantitative membrane proteomics identifies a novel role of mitochondria in healing injured muscles. J. Biol. Chem. 2012, 287:30455-30467.
26. Keyel P.A., Loultcheva L., Roth R., Salter R.D., Watkins S.C., Yokoyama W.M., Heuser J.E. Streptolysin O clearance through sequestration into blebs that bud passively from the plasma membrane. J. Cell Sci. 2011, 124:2414-2423.
27. Babiychuk E.B., Monastyrskaya K., Potez S., Draeger A. Blebbing confers resistance against cell lysis. Cell Death Differ. 2011, 18:80-89.
28. 2+-dependent endocytosis. J. Cell Biol. 2008, 180:905-914.
29. Morgan B.P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 1989, 264:1-14.
30. Moskovich O., Herzog L.O., Ehrlich M., Fishelson Z. Caveolin-1 and dynamin-2 are essential for removal of the complement C5b-9 complex via endocytosis. J. Biol. Chem. 2012, 287:19904-19915.
31. McNeil P.L., Steinhardt R.A. Plasma membrane disruption: repair, prevention, adaptation. Annu. Rev. Cell Dev. Biol. 2003, 19:697-731.
32. Abreu-Blanco M.T., Verboon J.M., Parkhurst S.M. Cell wound repair in Drosophila occurs through three distinct phases of membrane and cytoskeletal remodeling. J. Cell Biol. 2011, 193:455-464.
33. Bement W.M., Mandato C.A., Kirsch M.N. Wound-induced assembly and closure of an actomyosin purse string in Xenopus oocytes. Curr. Biol. 1999, 9:579-587.
34. Draeger A., Monastyrskaya K., Babiychuk E.B. Plasma membrane repair and cellular damage control: the annexin survival kit. Biochem. Pharmacol. 2011, 81:703-712.
35. Gerke V., Moss S.E. Annexins: from structure to function. Physiol. Rev. 2002, 82:331-371.
36. Miwa N., Uebi T., Kawamura S. S100-annexin complexes-biology of conditional association. FEBS J. 2008, 275:4945-4955.
37. Zhao X.Q., Naka M., Muneyuki M., Tanaka T. Ca(2+)-dependent inhibition of actin-activated myosin ATPase activity by S100C (S100A11), a novel member of the S100 protein family. Biochem. Biophys. Res. Commun. 2000, 267:77-79.
38. Hayes M.J., Rescher U., Gerke V., Moss S.E. Annexin-actin interactions. Traffic 2004, 5:571-576.
39. Moss S.E., Morgan R.O. The annexins. Genome Biol. 2004, 5:219.
40. Konopka-Postupolska D., Clark G., Goch G., Debski J., Floras K., Cantero A., Fijolek B., Roux S., Hennig J. The role of annexin 1 in drought stress in Arabidopsis. Plant Physiol. 2009, 150:1394-1410.
41. Clark G., Konopka-Postupolska D., Hennig J., Roux S. Is annexin 1 a multifunctional protein during stress responses?. Plant Signal Behav. 2010, 5:303-307.
42. Swairjo M.A., Concha N.O., Kaetzel M.A., Dedman J.R., Seaton B.A. Ca(2+)-bridging mechanism and phospholipid head group recognition in the membrane-binding protein annexin V. Nat. Struct. Biol. 1995, 2:968-974.
43. Rintala-Dempsey A.C., Rezvanpour A., Shaw G.S. S100-annexin complexes-structural insights. FEBS J. 2008, 275:4956-4966.
44. Marenholz I., Heizmann C.W., Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 2004, 322:1111-1122.
45. Santamaria-Kisiel L., Rintala-Dempsey A.C., Shaw G.S. Calcium-dependent and -independent interactions of the S100 protein family. Biochem. J. 2006, 396:201-214.
46. Osborn M., Johnsson N., Wehland J., Weber K. The submembranous location of p11 and its interaction with the p36 substrate of pp60 src kinase in situ. Exp. Cell Res. 1988, 175:81-96.
47. Seemann J., Weber K., Gerke V. Annexin I targets S100 C to early endosomes. FEBS Lett. 1997, 413:185-190.
48. Liu Y., Myrvang H.K., Dekker L.V. Annexin A2 complexes with S100 proteins: structure, function and pharmacological manipulation. Br. J. Pharmacol. 2014.
49. Lennon N.J., Kho A., Bacskai B.J., Perlmutter S.L., Hyman B.T., Brown R.H. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J. Biol. Chem. 2003, 278:50466-50473.
50. McNeil A.K., Rescher U., Gerke V., McNeil P.L. Requirement for annexin A1 in plasma membrane repair. J. Biol. Chem. 2006, 281:35202-35207.
51. Rhee H.J., Kim G.Y., Huh J.W., Kim S.W., Na D.S. Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydryl-reactive agent. Eur. J. Biochem. FEBS 2000, 267:3220-3225.
52. Bouter A., Gounou C., Berat R., Tan S., Gallois B., Granier T., d'Estaintot B.L., Poschl E., Brachvogel B., Brisson A.R. Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair. Nat. Commun. 2011, 2:270.
53. Roostalu U., Strahle U. In vivo imaging of molecular interactions at damaged sarcolemma. Dev. Cell 2012, 22:515-529.
54. Swaggart K.A., Demonbreun A.R., Vo A.H., Swanson K.E., Kim E.Y., Fahrenbach J.P., Holley-Cuthrell J., Eskin A., Chen Z., Squire K., Heydemann A., Palmer A.A., Nelson S.F., McNally E.M. Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:6004-6009.
55. Potez S., Luginbuhl M., Monastyrskaya K., Hostettler A., Draeger A., Babiychuk E.B. Tailored protection against plasmalemmal injury by annexins with different Ca2+ sensitivities. J. Biol. Chem. 2011, 286:17982-17991.
56. Newman R.H., Leonard K., Crumpton M.J. 2D crystal forms of annexin IV on lipid monolayers. FEBS Lett. 1991, 279:21-24.
57. Oling F., Bergsma-Schutter W., Brisson A. Trimers, dimers of trimers, and trimers of trimers are common building blocks of annexin a5 two-dimensional crystals. J. Struct. Biol. 2001, 133:55-63.
58. Kallunki T., Olsen O.D., Jaattela M. Cancer-associated lysosomal changes: friends or foes?. Oncogene 2013, 32:1995-2004.
59. Nylandsted J., Gyrd-Hansen M., Danielewicz A., Fehrenbacher N., Lademann U., Hoyer-Hansen M., Weber E., Multhoff G., Rohde M., Jaattela M. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J. Exp. Med. 2004, 200:425-435.
60. Petersen N.H., Olsen O.D., Groth-Pedersen L., Ellegaard A.M., Bilgin M., Redmer S., Ostenfeld M.S., Ulanet D., Dovmark T.H., Lonborg A., Vindelov S.D., Hanahan D., Arenz C., Ejsing C.S., Kirkegaard T., Rohde M., Nylandsted J., Jaattela M. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013, 24:379-393.
61. Ellegaard A.M., Groth-Pedersen L., Oorschot V., Klumperman J., Kirkegaard T., Nylandsted J., Jaattela M. Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol. Cancer Therap. 2013, 12:2018-2030.
62. Scharf B., Clement C.C., Wu X.X., Morozova K., Zanolini D., Follenzi A., Larocca J.N., Levon K., Sutterwala F.S., Rand J., Cobelli N., Purdue E., Hajjar K.A., Santambrogio L. Annexin A2 binds to endosomes following organelle destabilization by particulate wear debris. Nat. Commun. 2012, 3:755.
63. Swaminathan V., Mythreye K., O'Brien E.T., Berchuck A., Blobe G.C., Superfine R. Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res. 2011, 71:5075-5080.
64. Mussunoor S., Murray G.I. The role of annexins in tumour development and progression. J. Pathol. 2008, 216:131-140.
65. Salama I., Malone P.S., Mihaimeed F., Jones J.L. A review of the S100 proteins in cancer. Eur. J. Surg. Oncol. 2008, 34:357-364.
66. Melle C., Ernst G., Schimmel B., Bleul A., Von E.F. Colon-derived liver metastasis, colorectal carcinoma, and hepatocellular carcinoma can be discriminated by the Ca(2+)-binding proteins S100A6 and S100A11. PLoSOne 2008, 3:e3767.
67. Rehman I., Azzouzi A.R., Cross S.S., Deloulme J.C., Catto J.W., Wylde N., Larre S., Champigneuille J., Hamdy F.C. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. Hum. Pathol. 2004, 35:1385-1391.
68. Xiao M.B., Jiang F., Ni W.K., Chen B.Y., Lu C.H., Li X.Y., Ni R.Z. High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker. Med. Oncol. 2011.
69. Liu X., Ma D., Jing X., Wang B., Yang W., Qiu W. Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis. Med. Oncol. 2015, 32:392.
70. Shankar J., Messenberg A., Chan J., Underhill T.M., Foster L.J., Nabi I.R. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res. 2010, 70:3780-3790.
71. Egeblad M., Mortensen O.H., Jaattela M. Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Int. J. Cancer 2001, 94:185-191.
72. Rafn B., Nielsen C.F., Andersen S.H., Szyniarowski P., Corcelle-Termeau E., Valo E., Fehrenbacher N., Olsen C.J., Daugaard M., Egebjerg C., Bottzauw T., Kohonen P., Nylandsted J., Hautaniemi S., Moreira J., Jaattela M., Kallunki T. ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol. Cell. 2012, 45:764-776.
73. Rintala-Dempsey A.C., Santamaria-Kisiel L., Liao Y., Lajoie G., Shaw G.S. Insights into S100 target specificity examined by a new interaction between S100A11 and annexin A2. Biochemistry 2006, 45:14695-14705.
74. Togo T., Krasieva T.B., Steinhardt R.A. A decrease in membrane tension precedes successful cell-membrane repair. Mol. Biol. Cell. 2000, 11:4339-4346.
75. Miyake K., McNeil P.L., Suzuki K., Tsunoda R., Sugai N. An actin barrier to resealing. J. Cell Sci. 2001, 114:3487-3494.
76. Hayes M.J., Shao D., Bailly M., Moss S.E. Regulation of actin dynamics by annexin 2. EMBO J. 2006, 25:1816-1826.
77. Sakaguchi M., Miyazaki M., Inoue Y., Tsuji T., Kouchi H., Tanaka T., Yamada H., Namba M. Relationship between contact inhibition and intranuclear S100C of normal human fibroblasts. J. Cell Biol. 2000, 149:1193-1206.
78. Burkel B.M., Benink H.A., Vaughan E.M., von D.G., Bement W.M. A Rho GTPase signal treadmill backs a contractile array. Dev. Cell 2012, 23:384-396.
79. 2+-regulated phospholipid- and actin-binding proteins isolated from lung and placenta. J. Cell Biol. 1987, 104:503-511.
80. Morel E., Parton R.G., Gruenberg J. Annexin A2-dependent polymerization of actin mediates endosome biogenesis. Dev. Cell 2009, 16:445-457.
81. Lokman N.A., Ween M.P., Oehler M.K., Ricciardelli C. The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron. 2011, 4:199-208.
82. Yan X., Yin J., Yao H., Mao N., Yang Y., Pan L. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 2010, 70:1616-1624.
83. Kim A., Serada S., Enomoto T., Naka T. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary. Expert. Opin. Ther. Targets 2010, 14:963-971.
84. Hayes M.J., Moss S.E. Annexins and disease. Biochem. Biophys. Res. Commun. 2004, 322:1166-1170.
85. Reddy T.R., Li C., Guo X., Fischer P.M., Dekker L.V. Design, synthesis and SAR exploration of tri-substituted 1,2,4-triazoles as inhibitors of the annexin A2-S100A10 protein interaction. Bioorg. Med. Chem. 2014, 22:5378-5391.